Reducing Stiffness May Shield Muscles in Myotonic Dystrophy

A study published in Nature Communications has identified that myotonia — the persistent muscle stiffness characteristic of myotonic dystrophy type 1 (DM1) — acts as a primary driver of muscle degeneration rather than merely serving as a passive symptom. This discovery, detailed by researchers at University of Rochester Medicine, suggests that addressing stiffness directly may preserve muscle health even in the presence of the disease's underlying genetic mutations.

For decades, scientific consensus held that the primary pathology in DM1 was the production of toxic RNA that traps vital proteins, leading to widespread disruption in the genetic "splicing" process within cells. While these molecular defects are well-documented, the new research clarifies that the resulting electrical hyperexcitability of the muscles, which manifests as stiffness, amplifies the damage to muscle tissue.

Related imagery

"Our findings suggest that myotonia isn't simply an uncomfortable symptom people experience. It appears to amplify the harmful effects of the disease in muscles. When we eliminated myotonia in our mouse model, we didn't just improve muscle relaxation; we saw healthier muscles overall."

John Lueck, PhD, associate professor of Pharmacology and Physiology at University of Rochester Medicine

In the study, researchers utilized a mouse model of DM1 to genetically correct a specific chloride channel gene. This channel is responsible for the delayed muscle relaxation seen in patients. By "tuning down" the muscle's electrical activity, the team observed that the mice no longer exhibited stiffness and, notably, developed greater muscle force and healthier tissue structure. According to the research, this suggests that myotonia functions like a "volume knob" on the progression of the disease; by lowering the intensity of this electrical activity, the researchers slowed the degenerative impact on the muscle fibers, despite the toxic RNA still being present in the system.

Understanding Myotonic Dystrophy (DM)

Myotonic dystrophy is the most common form of muscular dystrophy affecting adults. The condition is categorized into two primary types:

• DM1 (Steinert disease): Caused by a CTG repeat expansion in the DMPK gene on chromosome 19. It often features significant muscle weakness, wasting, and cardiac or endocrine issues.
• DM2: Linked to a CCTG repeat expansion in the CNBP gene on chromosome 3. While clinically similar in some respects, DM2 typically presents later in adulthood and often follows a milder course than DM1.

While management currently focuses on physical and occupational therapy, respiratory support, and symptomatic relief, the new findings provide a potential shift in therapeutic priorities. Currently, many experimental strategies for DM1 aim to eliminate the toxic RNA entirely. The recent study suggests that therapies focusing on the chloride channel, and thus the reduction of myotonia, could serve as a valuable complement to these genetic treatments.

Existing medications used to manage stiffness in patients, such as mexiletine and ranolazine, may now warrant closer examination. While these drugs can alleviate symptoms, they are often underutilized due to side effects. The authors of the study indicate that developing safer, better-tolerated versions of these drugs could provide significant clinical benefits for those currently unable to access or tolerate existing treatments, or as a secondary intervention to protect muscle function.

Collaborative Research and Future Outlook

The research team included investigators from University of Rochester Medicine, Yale University, and the Friedrich-Baur-Institute. Their work received support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Myotonic Dystrophy Foundation, the National Institute of Dental and Craniofacial Research, the National Institute of General Medical Sciences, and the German Research Foundation.

Multidisciplinary care, incorporating physical therapy, rehabilitation, and management of systemic issues such as cardiac, respiratory, and gastrointestinal complications, remains the standard of care for patients. Moving forward, the scientific community continues to explore both genetic and symptomatic interventions, with researchers suggesting that the dual approach of targeting both the underlying toxic RNA and the resulting myotonia may offer the most effective path toward preserving functional independence in those living with DM1.